AKBA
Price
$3.65
Change
-$0.09 (-2.41%)
Updated
Jun 27 closing price
Capitalization
957.31M
32 days until earnings call
ATOS
Price
$0.89
Change
+$0.01 (+1.14%)
Updated
Jun 27 closing price
Capitalization
115.19M
50 days until earnings call
Interact to see
Advertisement

AKBA vs ATOS

Header iconAKBA vs ATOS Comparison
Open Charts AKBA vs ATOSBanner chart's image
Akebia Therapeutics
Price$3.65
Change-$0.09 (-2.41%)
Volume$8.51M
Capitalization957.31M
Atossa Therapeutics
Price$0.89
Change+$0.01 (+1.14%)
Volume$16.36M
Capitalization115.19M
AKBA vs ATOS Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. ATOS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Buy and ATOS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (AKBA: $3.74 vs. ATOS: $0.89)
Brand notoriety: AKBA and ATOS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 0% vs. ATOS: 1519%
Market capitalization -- AKBA: $958.62M vs. ATOS: $113.61M
AKBA [@Biotechnology] is valued at $958.62M. ATOS’s [@Biotechnology] market capitalization is $113.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileATOS’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • ATOS’s FA Score: 1 green, 4 red.
According to our system of comparison, ATOS is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 3 TA indicator(s) are bullish while ATOS’s TA Score has 6 bullish TA indicator(s).

  • AKBA’s TA Score: 3 bullish, 4 bearish.
  • ATOS’s TA Score: 6 bullish, 1 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а +1.63% price change this week, while ATOS (@Biotechnology) price change was +12.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

AKBA is expected to report earnings on Jul 31, 2025.

ATOS is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($957M) has a higher market cap than ATOS($115M). AKBA YTD gains are higher at: 96.842 vs. ATOS (-5.540). AKBA has higher annual earnings (EBITDA): 6.59M vs. ATOS (-28.04M). AKBA has more cash in the bank: 113M vs. ATOS (65.1M). ATOS has less debt than AKBA: ATOS (0) vs AKBA (54.1M). AKBA has higher revenues than ATOS: AKBA (185M) vs ATOS (0).
AKBAATOSAKBA / ATOS
Capitalization957M115M832%
EBITDA6.59M-28.04M-23%
Gain YTD96.842-5.540-1,748%
P/E RatioN/AN/A-
Revenue185M0-
Total Cash113M65.1M174%
Total Debt54.1M0-
FUNDAMENTALS RATINGS
AKBA vs ATOS: Fundamental Ratings
AKBA
ATOS
OUTLOOK RATING
1..100
4343
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3550
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is somewhat better than the same rating for AKBA (77) in the Biotechnology industry. This means that ATOS’s stock grew somewhat faster than AKBA’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.

ATOS's SMR Rating (97) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ATOS (50) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAATOS
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
N/A
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MUIFX32.310.21
+0.65%
Nationwide Institutional Service
EFCNX22.560.11
+0.49%
Emerald Insights Investor
PMGJX8.070.02
+0.25%
Principal MidCap Growth J
DCCAX28.31-0.05
-0.18%
Macquarie Small Cap Core A
EKWCX75.21-3.32
-4.23%
Allspring Precious Metals C

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
N/A
XERS - AKBA
42%
Loosely correlated
-0.84%
HOWL - AKBA
40%
Loosely correlated
-10.53%
ATOS - AKBA
39%
Loosely correlated
+1.64%
IPSC - AKBA
39%
Loosely correlated
-5.74%
ADAP - AKBA
39%
Loosely correlated
+1.16%
More

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+1.64%
ABOS - ATOS
46%
Loosely correlated
-7.44%
GBIO - ATOS
44%
Loosely correlated
-15.40%
IMNM - ATOS
43%
Loosely correlated
-0.23%
MGNX - ATOS
43%
Loosely correlated
-6.30%
NRIX - ATOS
43%
Loosely correlated
+0.17%
More